In a murine model of Alzheimer's disease (AD), intraperitoneal administration of recombinant human erythropoietin (EPO) resulted in significant improvements in memory function relative to saline-treated controls. Here, EPO is linked to early-onset autosomal dominant Alzheimer disease.